Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 79

1.

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM.

Blood. 2015 Jan 1;125(1):71-81. doi: 10.1182/blood-2014-07-588236. Epub 2014 Oct 21.

2.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A, Olavarría E, Schmitz N, Sureda A, Dreger P.

J Clin Oncol. 2014 Oct 10;32(29):3347-8. doi: 10.1200/JCO.2014.57.5597. Epub 2014 Aug 25. No abstract available.

PMID:
25154828
3.

Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.

Talpur R, Thompson A, Gangar P, Duvic M.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. doi: 10.1016/j.clml.2014.01.010. Epub 2014 Feb 4.

PMID:
24589156
4.

Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.

Kadin ME, Hughey LC, Wood GS.

J Am Acad Dermatol. 2014 Feb;70(2):374-6. doi: 10.1016/j.jaad.2013.09.007. No abstract available.

PMID:
24438952
5.

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela JM, Bachelez H, Bensussan A, Michel L, Bagot M.

Br J Dermatol. 2014 Mar;170(3):720-4. doi: 10.1111/bjd.12690.

PMID:
24438061
6.

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.

Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM.

Blood. 2014 Feb 20;123(8):1159-66. doi: 10.1182/blood-2013-09-525915. Epub 2013 Dec 11.

7.

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH.

JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.

8.

Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.

Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R.

J Clin Oncol. 2012 Nov 20;30(33):4091-7. doi: 10.1200/JCO.2011.39.8065. Epub 2012 Oct 8.

PMID:
23045580
9.

Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.

Elcin G, Duman N, Karahan S, Ersoy-Evans S, Erkin G, Karaduman A, Hapa A, Atakan N, Akan T, Sahin S.

J Dermatolog Treat. 2014 Jun;25(3):268-73. doi: 10.3109/09546634.2012.735638. Epub 2012 Dec 8.

PMID:
23030414
10.

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.

Eur J Cancer. 2013 Jan;49(2):386-94. doi: 10.1016/j.ejca.2012.08.017. Epub 2012 Sep 13.

PMID:
22981498
11.

Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M.

Clin Cancer Res. 2012 Sep 15;18(18):5051-60. doi: 10.1158/1078-0432.CCR-12-0604. Epub 2012 Jul 31.

12.

Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma.

Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, Hayes JP, Kuzel TM, Mittal BB.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):747-53. doi: 10.1016/j.ijrobp.2012.05.034. Epub 2012 Jul 17.

PMID:
22818412
13.

Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.

Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Alfonso Lombardo G, Rupoli S, Alaibac M, Bottoni U, Carbone A, Fava P, Fimiani M, Mamusa AM, Titli S, Zinzani PL, Bernengo MG; Gruppo Italiano Linfomi Cutanei..

Cancer. 2012 Dec 1;118(23):5830-9. doi: 10.1002/cncr.27627. Epub 2012 Jun 6.

14.

Sézary syndrome: a study of 176 patients at Mayo Clinic.

Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR.

J Am Acad Dermatol. 2012 Dec;67(6):1189-99. doi: 10.1016/j.jaad.2012.04.043. Epub 2012 May 27.

PMID:
22640839
15.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.

Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6.

16.

Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008908. doi: 10.1002/14651858.CD008908.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD008908.

PMID:
22258991
17.

Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.

Benner MF, Jansen PM, Vermeer MH, Willemze R.

Blood. 2012 Feb 16;119(7):1643-9. doi: 10.1182/blood-2011-08-376319. Epub 2011 Dec 12.

18.

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas.; United States Cutaneous Lymphoma Consortium.; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer..

J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.

19.

The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides.

Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT.

Arch Dermatol. 2011 May;147(5):561-7. doi: 10.1001/archdermatol.2011.98.

PMID:
21576575
20.

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M.

J Am Acad Dermatol. 2011 Feb;64(2):352-404. doi: 10.1016/j.jaad.2010.08.037. Epub 2010 Dec 9. Review.

PMID:
21145619

Supplemental Content

Support Center